

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Ovarian cancer	Fatty acid binding protein 4 adipocyte (FABP4)	<p>Patient tissue and mouse studies suggest inhibiting FABP4 could decrease ovarian cancer metastases. Ovarian cancer frequently metastasizes to the omentum, an organ in the abdominal cavity composed primarily of adipocytes. In tumor tissue from ovarian cancer patients, FABP4 was expressed in omental metastatic tumors at the adipocyte interface but not in the corresponding primary tumor. In a mouse model of ovarian cancer, Fabp4 deficiency lowered metastases compared with no deficiency (<math>p &lt; 0.001</math>). Next steps include testing small molecule FABP4 inhibitors in the mouse model.</p> <p><b>SciBX 4(44); doi:10.1038/scibx.2011.1233</b>  <b>Published online Nov. 10, 2011</b></p>	Patent application filed; available for licensing	<p>Nieman, K.M. <i>et al. Nat. Med.</i>; published online Oct. 30, 2011; doi:10.1038/nm.2492</p> <p><b>Contact:</b> Ernst Lengyel, The University of Chicago, Chicago, Ill.            e-mail: <a href="mailto:elengyel@uchicago.edu">elengyel@uchicago.edu</a></p>